• Mutation; HGNC; HGNC:171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Unspecified (PubMed=27325687).
  
• Mutation; HGNC; HGNC:4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=27325687; PubMed=34732238).
  
• Mutation; HGNC; HGNC:9277; PPM1D; Simple; p.Pro428Glnfs*3 (c.1283delC); Zygosity=Unspecified (PubMed=32229503; PubMed=34732238).
  

PubMed=25628092; DOI=10.1038/bjc.2015.16; PMCID=PMC4333505
Cockle J.V., Picton S., Levesley J., Ilett E.J., Carcaboso A.M., Short S., Steel L.P., Melcher A., Lawler S.E., Bruning-Richardson A.
Cell migration in paediatric glioma; characterisation and potential therapeutic targeting.
Br. J. Cancer 112:693-703(2015)

PubMed=27325687; DOI=10.1158/1535-7163.MCT-15-0558
Jansen M.H.A., Lagerweij T., Sewing A.C.P., Vugts D.J., van Vuurden D.G., Molthoff C.F.M., Caretti V., Veringa S.J.E., Petersen N., Carcaboso A.M., Noske D.P., Vandertop W.P., Wesseling P., van Dongen G.A.M.S., Kaspers G.J.L., Hulleman E.
Bevacizumab targeting diffuse intrinsic pontine glioma: results of 89Zr-bevacizumab PET imaging in brain tumor models.
Mol. Cancer Ther. 15:2166-2174(2016)

PubMed=28947132; DOI=10.1016/j.yexcr.2017.09.032
Meel M.H., Sewing A.C.P., Waranecki P., Metselaar D.S., Wedekind L.E., Koster J., van Vuurden D.G., Kaspers G.J.L., Hulleman E.
Culture methods of diffuse intrinsic pontine glioma cells determine response to targeted therapies.
Exp. Cell Res. 360:397-403(2017)

PubMed=31439867; DOI=10.1038/s41467-019-11732-6; PMCID=PMC6706443
Fons N.R., Sundaram R.K., Breuer G.A., Peng S., McLean R.L., Kalathil A.N., Schmidt M.S., Carvalho D.M., Mackay A., Jones C., Carcaboso A.M., Nazarian J., Berens M.E., Brenner C., Bindra R.S.
PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma.
Nat. Commun. 10:3790.1-3790.10(2019)

PubMed=32229503; DOI=10.1158/1541-7786.MCR-19-0507
Wang Z.-H., Xu C., Diplas B.H., Moure C.J., Chen C.-P.J., Chen L.H., Du C.-Z., Zhu H.-S., Greer P.K., Zhang L.-W., He Y.-P., Waitkus M.S., Yan H.
Targeting mutant PPM1D sensitizes diffuse intrinsic pontine glioma cells to the PARP inhibitor olaparib.
Mol. Cancer Res. 18:968-980(2020)

PubMed=34732238; DOI=10.1186/s40478-021-01270-y; PMCID=PMC8565061
Xu C., Liu H., Pirozzi C.J., Chen L.H., Greer P.K., Diplas B.H., Zhang L.-W., Waitkus M.S., He Y.-P., Yan H.
TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
Acta Neuropathol. Commun. 9:178.1-178.12(2021)